Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
From Jan 2020: how each company's value moved, whatever its size.
US$ billions, as reported in each year's annual results.
Free cash flow as a share of revenue. US dollars at each year's exchange rate.
| Measure | BeyondSpring Inc.✕ BYSI · #24,101 in the world | Cell Source, Inc.✕ CLCS |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Founded | 2010 | — |
| Size | ||
| Market cap | ||
The largest companies, each against its nearest peers in value from the same industry.
Fewer than two years of free cash flow margin are on file for these companies.
| $22 M |
| $20 M* |
| Net income | $-1 M▲ best | $-5 M |
|---|
| Valuation | ||
|---|---|---|
| Free cash flow yield | -92.1% | — |
| Altman Z-score zone | — | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap Dec 2022; ratios FY2024 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.